Literature DB >> 8228370

Comparison of the efficacy of polyenes and triazoles against hematogenous Candida krusei infection in neutropenic mice.

N C Karyotakis1, E J Anaissie, R Hachem, M C Dignani, G Samonis.   

Abstract

Candida krusei is reported to cause serious infections in immunocompromised patients, particularly those receiving prophylaxis with antifungal azoles. Treatment of this infection can be very challenging. The efficacy of amphotericin B, liposomal amphotericin B (three dosages), fluconazole, and D0870 (a new experimental oral bis-triazole) was assessed in a CF1 mouse model of hematogenous C. krusei infection. Increased survival time and reduced kidney fungal burden were achieved with treatment with amphotericin B at 2 mg/kg/day and liposomal amphotericin B at 8 and 15 mg/kg/day. D0870 at 25 mg/kg/day increased survival time but had no effect on clearance from organs, while the survival and clearance from organs of mice treated with fluconazole at a dose of 100 mg/kg/day did not differ from those of untreated animals. These findings suggest that deoxycholate and liposome-encapsulated amphotericin B are active against disseminated C. krusei infection in neutropenic mice and confirm the in vitro and in vivo resistance of this species to fluconazole.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8228370     DOI: 10.1093/infdis/168.5.1311

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

1.  Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.

Authors:  Jon A Olson; Jill P Adler-Moore; P J Smith; Richard T Proffitt
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

2.  Thirteen-year evolution of azole resistance in yeast isolates and prevalence of resistant strains carried by cancer patients at a large medical center.

Authors:  C R Boschman; U R Bodnar; M A Tornatore; A A Obias; G A Noskin; K Englund; M A Postelnick; T Suriano; L R Peterson
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

Review 3.  Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis.

Authors:  A J Coukell; R N Brogden
Journal:  Drugs       Date:  1998-04       Impact factor: 9.546

4.  International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program.

Authors:  M A Pfaller; D J Diekema; R N Jones; H S Sader; A C Fluit; R J Hollis; S A Messer
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

5.  In vitro activity of nystatin compared with those of liposomal nystatin, amphotericin B, and fluconazole against clinical Candida isolates.

Authors:  Sevtap Arikan; Luis Ostrosky-Zeichner; Mario Lozano-Chiu; Victor Paetznick; David Gordon; Tom Wallace; John H Rex
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

6.  Treatment of disseminated Torulopsis glabrata infection with DO870 and amphotericin B.

Authors:  B A Atkinson; R Bocanegra; A L Colombo; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

7.  Activities of D0870, a novel triazole, against Candida lusitaniae and Trichosporon beigelii in experimental murine infections.

Authors:  N C Karyotakis; M C Dignani; R Hachem; E J Anaissie
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

Review 8.  Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.

Authors:  K L Goa; L B Barradell
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

9.  SCH 51048, a new antifungal triazole active against hematogenous Candida krusei infections in neutropenic mice.

Authors:  N C Karyotakis; M C Dignani; E J Anaissie
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

10.  Antifungal efficacy during Candida krusei infection in non-conventional models correlates with the yeast in vitro susceptibility profile.

Authors:  Liliana Scorzoni; Maria Pilar de Lucas; Ana Cecilia Mesa-Arango; Ana Marisa Fusco-Almeida; Encarnación Lozano; Manuel Cuenca-Estrella; Maria Jose Mendes-Giannini; Oscar Zaragoza
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.